Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor
about
Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors.Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitorsBinding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bondingA comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutantsCrystal Structure of Venezuelan Hemorrhagic Fever Virus Fusion Glycoprotein Reveals a Class 1 Postfusion Architecture with Extensive Glycosylation3'-Azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changesDelavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)Structure-based design of novel dihydroalkoxybenzyloxopyrimidine derivatives as potent nonnucleoside inhibitors of the human immunodeficiency virus reverse transcriptase"Mixed inhibitors" of HIV-reverse transcriptase: synthesis and antiviral activityStructure-based design of non-nucleoside reverse transcriptase inhibitors of drug-resistant human immunodeficiency virusCharacteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-11,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activityS-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors.Novel Cyclopropyl-Indole Derivatives as HIV Non-Nucleoside Reverse Transcriptase Inhibitors.Small-molecule and mutational analysis of allosteric Eg5 inhibition by monastrolSynthesis and antiviral activity of C-5 substituted analogues of d4T bearing methylamino- or methyldiamino-linker arms.Search for non-nucleoside inhibitors of HIV-1 reverse transcriptase using chemical similarity, molecular docking, and MM-GB/SA scoringThe P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activitiesA novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.Cross-linking of the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase to template-primerMutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture.Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding.Steered molecular dynamics simulation on the binding of NNRTI to HIV-1 RT.N-3 Hydroxylation of Pyrimidine-2,4-diones Yields Dual Inhibitors of HIV Reverse Transcriptase and IntegraseModulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules.Ligand similarity guided receptor selection enhances docking accuracy and recall for non-nucleoside HIV reverse transcriptase inhibitors.Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile.Efavirenz for HIV-1 infection in adults: an overview.Subunit-selective mutational analysis and tissue culture evaluations of the interactions of the E138K and M184I mutations in HIV-1 reverse transcriptase.Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase.Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analysesMolecular mechanism of antagonism between the Y181C and E138K mutations in HIV-1 reverse transcriptaseProtein-mediated antagonism between HIV reverse transcriptase ligands nevirapine and MgATP.Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.Nonnucleoside inhibitor binding affects the interactions of the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase with DNARole of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitorsClinical significance of HIV reverse-transcriptase inhibitor-resistance mutations.Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005 - 2010).Synthesis, biological evaluation and molecular modeling of 2-Hydroxyisoquinoline-1,3-dione analogues as inhibitors of HIV reverse transcriptase associated ribonuclease H and polymerase.
P2860
Q24540388-3DEF3D8B-D4C0-43A4-8E5E-C39A155F9343Q26777448-A2DD19F0-642F-4FA5-95C7-A6F4E0D162F4Q27622387-A19EDC38-FA26-41A9-9426-04231466FEF4Q27675380-2ABFC458-C41F-4219-8221-348631E60040Q27679988-B6132C3A-0771-4FCB-81E6-E4C77ABF7380Q27764900-9F5EAA51-E5D4-4AFD-89C3-1EFBBC7DAEB1Q28343932-C01FCD77-E760-4BAE-A5FE-DD8FAE371E38Q28369309-9DADEF90-ACB7-4E9A-A611-2F7D07E55C69Q28370027-CA24B470-33B0-4F10-88D1-D08C40943127Q28376938-BC64C852-9BDB-45C5-AA30-E7757E290AAFQ28379192-31F32BF4-5C8C-4D1E-AABF-487A3B06647CQ28379406-ACE60F62-2F61-476D-94A6-07A3F5F14AD4Q28379544-5F00A860-138A-44B4-BAAF-7F20D5B2A5FAQ30342229-448F9C8A-9EDD-4789-8850-FB07F70F52E1Q30363318-427245EE-6F32-42AA-A66D-6439671E957FQ30477178-7C21A528-F3DE-4FC3-9E7B-C4A0497291D7Q31406951-70CA0626-4803-4B42-B1C6-7A329630D2E8Q33303221-8497734A-8769-4B8D-8176-351F6809594BQ33815628-DCAEF88B-DE5D-47A6-A7C7-82B1D1E05AD2Q33826904-0C5261E1-CF9D-496B-8324-72ED6FACFD94Q33845922-7EC74068-1D93-4A44-B42F-F325D25C82D8Q33873983-3D524F72-BA96-46B0-ABD8-E6065EC7F5D0Q34163065-9B91083E-42B1-43B4-951C-0C467A7815BDQ34181367-168BF567-2AAE-4C65-A95B-C6117EB47006Q34779869-59D842A8-8F38-48ED-A1E9-A77697FDFADBQ34976859-8FF9DA36-B5EA-40AE-88E2-CE86C859C485Q35801074-C58ECCA7-1F66-4D57-8A91-BD27D1EEA778Q35851936-233278F9-B84F-4457-AD14-C2BEDD14048BQ35917519-2AFF6B62-EF45-4F72-BCE7-7DFE9E561740Q36172087-3BBA0E42-A7B6-422B-BFD9-8BA2E65F38A4Q36297904-7B170134-BDB1-415E-8997-924324DC085AQ36388297-B5E3CDC2-C939-4F46-A003-E1207CD6E193Q36397384-B63BAB74-B66A-49B2-934B-F82243BDEDCCQ36939750-45B4F7D6-6D76-47B1-B2BE-6332876162C1Q36969977-755B9151-940C-44D8-9944-74659B4B4B45Q37011076-569E303F-2955-4B8F-B04E-F3544A09FB59Q37263541-612A69D0-2952-4A59-A802-75026FCB8E68Q37859395-DF58E181-338B-4DBD-87B0-0608B3B95A58Q37860335-CE1A5E4D-E506-46F0-84F0-B17EB4E1FBCAQ38849909-21B04F90-18B5-430F-9B81-BB46664F5356
P2860
Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor
description
1997 nî lūn-bûn
@nan
1997 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Unique features in the structu ...... r this nonnucleoside inhibitor
@ast
Unique features in the structu ...... r this nonnucleoside inhibitor
@en
Unique features in the structu ...... r this nonnucleoside inhibitor
@nl
type
label
Unique features in the structu ...... r this nonnucleoside inhibitor
@ast
Unique features in the structu ...... r this nonnucleoside inhibitor
@en
Unique features in the structu ...... r this nonnucleoside inhibitor
@nl
prefLabel
Unique features in the structu ...... r this nonnucleoside inhibitor
@ast
Unique features in the structu ...... r this nonnucleoside inhibitor
@en
Unique features in the structu ...... r this nonnucleoside inhibitor
@nl
P2093
P2860
P50
P356
P1476
Unique features in the structu ...... r this nonnucleoside inhibitor
@en
P2093
A L Hopkins
D K Stammers
R M Esnouf
P2860
P304
P356
10.1073/PNAS.94.8.3984
P407
P577
1997-04-01T00:00:00Z